SDS of cas: 20198-19-0. The reaction of aromatic heterocyclic molecules with protons is called protonation. Aromatic heterocycles are more basic than benzene due to the participation of heteroatoms. Compound: 2-Aminoquinazolin-4(3H)-one, is researched, Molecular C8H7N3O, CAS is 20198-19-0, about EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. Author is Brennecke, Philip; Rasina, Dace; Aubi, Oscar; Herzog, Katja; Landskron, Johannes; Cautain, Bastien; Vicente, Francisca; Quintana, Jordi; Mestres, Jordi; Stechmann, Bahne; Ellinger, Bernhard; Brea, Jose; Kolanowski, Jacek L.; Pilarski, Radoslaw; Orzaez, Mar; Pineda-Lucena, Antonio; Laraia, Luca; Nami, Faranak; Zielenkiewicz, Piotr; Paruch, Kamil; Hansen, Espen; von Kries, Jens P.; Neuenschwander, Martin; Specker, Edgar; Bartunek, Petr; Simova, Sarka; Lesnikowski, Zbigniew; Krauss, Stefan; Lehtioe, Lari; Bilitewski, Ursula; Broenstrup, Mark; Tasken, Kjetil; Jirgensons, Aigars; Lickert, Heiko; Clausen, Mads H.; Andersen, Jeanette H.; Vicent, Maria J.; Genilloud, Olga; Martinez, Aurora; Nazare, Marc; Fecke, Wolfgang; Gribbon, Philip.
A review. Compound screening in biol. assays and subsequent optimization of hits is indispensable for the development of new mol. research tools and drug candidates. To facilitate such discoveries, the European Research Infrastructure EU-OPENSCREEN was founded recently with the support of its member countries and the European Commission. Its distributed character harnesses complementary knowledge, expertise, and instrumentation in the discipline of chem. biol. from 20 European partners, and its open working model ensures that academia and industry can readily access EU-OPENSCREEN’s compound collection, equipment, and generated data. To demonstrate the power of this collaborative approach, this perspective article highlights recent projects from EU-OPENSCREEN partner institutions. These studies yielded (1) 2-aminoquinazolin-4(3H)-ones as potential lead structures for new antimalarial drugs, (2) a novel lipodepsipeptide specifically inducing apoptosis in cells deficient for the pVHL tumor suppressor, (3) small-mol.-based ROCK inhibitors that induce definitive endoderm formation and can potentially be used for regenerative medicine, (4) potential pharmacol. chaperones for inborn Errors of metabolism and a familiar form of acute myeloid leukemia (AML), and (5) novel tankyrase inhibitors that entered a lead-to-candidate program. Collectively, these findings highlight the benefits of small-mol. screening, the plethora of assay designs, and the close connection between screening and medicinal chem. within EU-OPENSCREEN.
Here is a brief introduction to this compound(20198-19-0)SDS of cas: 20198-19-0, if you want to know about other compounds related to this compound(20198-19-0), you can read my other articles.
Reference:
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis—I. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis